Neuro Startup Makes Debut With $20.9M From Novo, Johnson & Johnson Post author:Sam Post published:February 8, 2018 Post category:BioPharma Syndesi will work to modulate the synaptic vesicle protein SV2A. Source: BioSpace You Might Also Like Nativis, Inc. Convenes Inaugural Ultra-Low Radio Frequency Energy Technology Advisory Board (TAB) Meeting March 13, 2017 Top 3 Takeover Targets for Pfizer January 22, 2018 Merck's Cyber Attack Could Cost Insurers $275M October 19, 2017
Nativis, Inc. Convenes Inaugural Ultra-Low Radio Frequency Energy Technology Advisory Board (TAB) Meeting March 13, 2017
